QLS31905 + gemcitabine + cisplatin + QL2107

QLS31905 + gemcitabine + cisplatin + QL2107 is a combination regimen under investigation primarily for advanced solid tumors, especially in patients with Claudin18.2-positive cancers. QLS31905 is a bispecific antibody developed by Qilu Pharmaceutical targeting Claudin18.2 and CD3, aiming to redirect T cells to kill Claudin18.2-expressing tumor cells[1][5]. QL2107 is a biosimilar of pembrolizumab (a PD-1 inhibitor) designed to block the PD-1 pathway, thus reactivating T cell antitumor immunity[2][4][8]. Gemcitabine and cisplatin are established chemotherapeutics interfering with DNA synthesis and repair. This combination is undergoing clinical evaluation for first-line and later-line treatment of solid tumors such as biliary tract cancer, pancreatic cancer, and other gastrointestinal tumors[1][3]. - **QLS31905**: Bispecific antibody (Claudin18.2 and CD3) – induces T cell–mediated cytotoxicity[1][5]. - **QL2107**: Pembrolizumab biosimilar – immune checkpoint inhibitor targeting PD-1[2][4][8]. - **Gemcitabine and cisplatin**: Small molecule cytotoxic chemotherapies. Qilu Pharmaceutical is the developer and sponsor for all components and related combination trials[1][2][4][8]. This regimen is in multiple Phase 2 studies in China, mainly for advanced gastrointestinal cancers positive for Claudin18.2[1][3].